• Elemental quantification and analysis of structural abnormalities in neurons from Parkinson’s-diseased brains by X-ray fluorescence microscopy and diffraction.
    Joppe K, Nicolas JD, Grünewald TA, Eckermann M, Salditt T, Lingor P.
    Biomed. Opt. Express. 2020 11(4).

  • Inhibition of the autophagic protein ULK1 attenuates axonal degeneration in vitro and in vivo, enhances translation, and modulates splicing.
    Vahsen BF, Ribas VT, Sundermeyer J, Boecker A, Dambeck V, Lenz C, Shomroni O, Caldi Gomes L, Tatenhorst L, Barski E, Roser AE, Michel U, Urlaub H, Salinas G, Bähr M, Koch JC, Lingor P.
    Cell Death Differ. 2020 Apr 27. doi: 10.1038/s41418-020-0543-y. Online ahead of print.

  • Compassionate Use of the ROCK Inhibitor Fasudil in Three Patients With Amyotrophic Lateral Sclerosis.
    Koch JC, Kuttler J, Maass F, Lengenfeld T, Zielke E, Bähr M, Lingor P.
    Front Neurol. 2020 Mar 13;11:173. doi: 10.3389/fneur.2020.00173. eCollection 2020.

  • Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.
    Hagenacker T, Wurster CD, Günther R, Schreiber-Katz O, Osmanovic A, Petri S, Weiler M, Ziegler A, Kuttler J, Koch JC, Schneider I, Wunderlich G, Schloss N, Lehmann HC, Cordts I, Deschauer M, Lingor P, Kamm C, Stolte B, Pietruck L, Totzeck A, Kizina K, Mönninghoff C, von Velsen O, Ose C, Reichmann H, Forsting M, Pechmann A, Kirschner J, Ludolph AC, Hermann A, Kleinschnitz C.
    Lancet Neurol. 2020 Apr;19(4):317-325. doi: 10.1016/S1474-4422(20)30037-5. Epub 2020 Mar 18.

  • Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study.
    Reichmann H, Lees A, Rocha JF, Magalhães D, Soares-da-Silva P; OPTIPARK investigators.
    Transl Neurodegener. 2020 Mar 4;9:9. doi: 10.1186/s40035-020-00187-1. eCollection 2020.

  • Radiation dose reduction for CT-guided intrathecal nusinersen administration in adult patients with spinal muscular atrophy.
    Cordts I, Deschauer M, Lingor P, Burian E, Baum T, Zimmer C, Maegerlein C, Sollmann N.
    Sci Rep. 2020 Feb 25;10(1):3406. doi: 10.1038/s41598-020-60240-x.

  • Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy.
    Cordts I, Lingor P, Friedrich B, Pernpeintner V, Zimmer C, Deschauer M, Maegerlein C.
    Ther Adv Neurol Disord. 2020 Jan 20;13:1756286419887616. doi: 10.1177/1756286419887616. eCollection 2020.

  • Chromogranin A Analysis in the Differential Diagnosis Across Lewy Body Disorders.
    Gmitterova K, Varges D, Schmitz M, Zafar S, Maass F, Lingor P, Zerr I.
    J Alzheimers Dis. 2020;73(4):1355-1361. doi: 10.3233/JAD-191153.

  • SQSTM1/p62 variants in 486 patients with familial ALS from Germany and Sweden.
    Yilmaz R, Müller K, Brenner D, Volk AE, Borck G, Hermann A, Meitinger T, Strom TM, Danzer KM, Ludolph AC, Andersen PM, Weishaupt JH; German ALS Network MND-NET.
    Neurobiol Aging. 2020 Mar;87:139.e9-139.e15. doi: 10.1016/j.neurobiolaging.2019.10.018. Epub 2019 Nov 2.



  • Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen.
    Wurster CD, Koch JC, Cordts I, Dreyhaupt J, Otto M, Uzelac Z, Witzel S, Winter B, Kocak T, Schocke M, Weydt P, Wollinsky K, Ludolph AC, Deschauer M, Lingor P, Tumani H, Hermann A, Günther R.
    Front Neurol. 2019 Nov 7;10:1179. doi: 10.3389/fneur.2019.01179. eCollection 2019.

  • Patient-Reported Prevalence of Non-motor Symptoms Is Low in Adult Patients Suffering From 5q Spinal Muscular Atrophy.
    Günther R, Wurster CD, Cordts I, Koch JC, Kamm C, Petzold D, Aust E, Deschauer M, Lingor P, Ludolph AC, Hermann A.
    Front Neurol. 2019 Nov 1;10:1098. doi: 10.3389/fneur.2019.01098. eCollection 2019.

  • Elemental fingerprint: Reassessment of a cerebrospinal fluid biomarker for Parkinson’s disease.
    Maass F, Michalke B, Willkommen D, Leha A, Schulte C, Tönges L, Mollenhauer B, Trenkwalder C, Rückamp D, Börger M, Zerr I, Bähr M, Lingor P.
    Neurobiol Dis. 2019 Nov 13;134:104677. doi: 10.1016/j.nbd.2019.104677. [Epub ahead of print]


  • Selenium speciation analysis in the cerebrospinal fluid of patients with Parkinson’s disease.
    Maass F, Michalke B, Willkommen D, Schulte C, Tönges L, Boerger M, Zerr I, Bähr M, Lingor P.
    J Trace Elem Med Biol. 2020 Jan;57:126412. doi: 10.1016/j.jtemb.2019.126412. Epub 2019 Sep 24.

  • Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.
    Wurster CD, Steinacker P, Günther R, Koch JC, Lingor P, Uzelac Z, Witzel S, Wollinsky K, Winter B, Osmanovic A, Schreiber-Katz O, Al Shweiki R, Ludolph AC, Petri S, Hermann A, Otto M; MND-Net.
    J Neurol. 2019 Sep 24. doi: 10.1007/s00415-019-09547-y. [Epub ahead of print]


  • AAV-Mediated Expression of Dominant-Negative ULK1 Increases Neuronal Survival and Enhances Motor Performance in the MPTP Mouse Model of Parkinson’s Disease.
    Balke D, Tatenhorst L, Dambeck V, Ribas VT, Vahsen BF, Michel U, Bähr M, Lingor P.
    Mol Neurobiol. 2019 Aug 24. doi: 10.1007/s12035-019-01744-0. [Epub ahead of print]


  • Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment.
    Wurster CD, Günther R, Steinacker P, Dreyhaupt J, Wollinsky K, Uzelac Z, Witzel S, Kocak T, Winter B, Koch JC, Lingor P, Petri S, Ludolph AC, Hermann A, Otto M.
    Ther Adv Neurol Disord. 2019 May 10;12:1756286419846058. doi: 10.1177/1756286419846058. eCollection 2019.

  • Dyskinesia in multiple system atrophy and progressive supranuclear palsy.
    Jost WH, Lingor P, Tönges L, Schwarz J, Buhmann C, Kassubek J, Schrag A.
    J Neural Transm (Vienna). 2019 Jul;126(7):925-932. doi: 10.1007/s00702-019-02012-0. Epub 2019 May 13. Review.

  • ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis.
    Lingor P, Weber M, Camu W, Friede T, Hilgers R, Leha A, Neuwirth C, Günther R, Benatar M, Kuzma-Kozakiewicz M, Bidner H, Blankenstein C, Frontini R, Ludolph A, Koch JC; ROCK-ALS Investigators.
    Front Neurol. 2019 Mar 27;10:293. doi: 10.3389/fneur.2019.00293. eCollection 2019.

  • Prognostic factors in ALS: a comparison between Germany and China.
    Dorst J, Chen L, Rosenbohm A, Dreyhaupt J, Hübers A, Schuster J, Weishaupt JH, Kassubek J, Gess B, Meyer T, Weyen U, Hermann A, Winkler J, Grehl T, Hagenacker T, Lingor P, Koch JC, Sperfeld A, Petri S, Großkreutz J, Metelmann M, Wolf J, Winkler AS, Klopstock T, Boentert M, Johannesen S, Storch A, Schrank B, Zeller D, Liu XL, Tang L, Fan DS, Ludolph AC.
    J Neurol. 2019 Jun;266(6):1516-1525. doi: 10.1007/s00415-019-09290-4. Epub 2019 Mar 28.

  • Proteomic analysis of tear fluid reveals disease-specific patterns in patients with Parkinson’s disease – A pilot study.
    Boerger M, Funke S, Leha A, Roser AE, Wuestemann AK, Maass F, Bähr M, Grus F, Lingor P.
    Parkinsonism Relat Disord. 2019 Jun;63:3-9. doi: 10.1016/j.parkreldis.2019.03.001. Epub 2019 Mar 6.

  • The Contribution of Iron to Protein Aggregation Disorders in the Central Nervous System.
    Joppe K, Roser AE, Maass F, Lingor P.
    Front Neurosci. 2019 Jan 22;13:15. doi: 10.3389/fnins.2019.00015. eCollection 2019.



  • Circulating miRNAs as Diagnostic Biomarkers for Parkinson’s Disease.
    Roser AE, Caldi Gomes L, Schünemann J, Maass F, Lingor P.
    Front Neurosci. 2018 Sep 5;12:625. doi: 10.3389/fnins.2018.00625. eCollection 2018. Review.

  • Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy.
    Schmitz M, Villar-Piqué A, Llorens F, Gmitterová K, Hermann P, Varges D, Zafar S, Lingor P, Vanderstichele H, Demeyer L, Stoops E, Trojanowski JQ, Lee VM, Zerr I.
    Mol Neurobiol. 2019 May;56(5):3476-3483. doi: 10.1007/s12035-018-1313-4. Epub 2018 Aug 22.

  • Bioelemental patterns in the cerebrospinal fluid as potential biomarkers for neurodegenerative disorders.
    Maass F, Lingor P.
    Neural Regen Res. 2018 Aug;13(8):1356-1357. doi: 10.4103/1673-5374.235239. No abstract available.

  • Alpha-synuclein deregulates the expression of COL4A2 and impairs ER-Golgi function.
    Paiva I, Jain G, Lázaro DF, Jerčić KG, Hentrich T, Kerimoglu C, Pinho R, Szegő ÈM, Burkhardt S, Capece V, Halder R, Islam R, Xylaki M, Caldi Gomes LA, Roser AE, Lingor P, Schulze-Hentrich JM, Borovečki F, Fischer A, Outeiro TF.
    Neurobiol Dis. 2018 Nov;119:121-135. doi: 10.1016/j.nbd.2018.08.001. Epub 2018 Aug 6.

  • miR-182-5p and miR-183-5p Act as GDNF Mimics in Dopaminergic Midbrain Neurons.
    Roser AE, Caldi Gomes L, Halder R, Jain G, Maass F, Tönges L, Tatenhorst L, Bähr M, Fischer A, Lingor P.
    Mol Ther Nucleic Acids. 2018 Jun 1;11:9-22. doi: 10.1016/j.omtn.2018.01.005. Epub 2018 Feb 2.

  • [Treatment of end-of-dose fluctuations: the need for an individualized approach].
    Lingor P, Claßen J, Herbst H, Storch A, Urban P, Wellach I, Jost WH.
    Fortschr Neurol Psychiatr. 2018 Sep;86(S 01):S59-S62. doi: 10.1055/a-0583-8460. Epub 2018 Jul 18. Review. German.

  • ROCK inhibition in models of neurodegeneration and its potential for clinical translation.
    Koch JC, Tatenhorst L, Roser AE, Saal KA, Tönges L, Lingor P.
    Pharmacol Ther. 2018 Apr 3. pii: S0163-7258(18)30056-1. doi: 10.1016/j.pharmthera.2018.03.008. [Epub ahead of print] Review.

  • Elemental fingerprint as a cerebrospinal fluid biomarker for the diagnosis of Parkinson’s disease.
    Maass F, Michalke B, Leha A, Börger M, Zerr I, Koch JC, Tönges L, Bähr M, Lingor P.
    J Neurochem 2018 in press. DOI: 10.1111/jnc.14316 PubMed

  • Hot-spot KIF5A mutations cause familial ALS.
    Brenner D, Yilmaz R, Müller K, Grehl T, Petri S, Meyer T, Grosskreutz J, Weydt P, Ruf W, Neuwirth C, Weber M, Pinto S, Claeys KG, Schrank B, Jordan B, Knehr A, Günther K, Hübers A, Zeller D; German ALS network MND-NET , Kubisch C, Jablonka S, Sendtner M, Klopstock T, de Carvalho M, Sperfeld A, Borck G, Volk AE, Dorst J, Weis J, Otto M, Schuster J, Del Tredici K, Braak H, Danzer KM, Freischmidt A, Meitinger T, Strom TM, Ludolph AC, Andersen PM, Weishaupt JH.
    Brain. 2018 Jan 12. doi: 10.1093/brain/awx370. PubMed

  • Restoration of Bi-contrast MRI Data for Intensity Uniformity with Bayesian Coring of Co-occurrence Statistics.
    Hadjidemetriou S, Psychogio MN, Lingor P, von Eckardstein K, Papageorgiou I.
    J Imaging 2018 in press.

  • miR-182-5p and miR-183-5p act as GDNF mimics in dopaminergic midbrain neurons.
    Roser AE, Caldi Gomes L, Halder R, Jain G, Maass F, Tönges L, Tatenhorst L, Bähr M, Fischer A, Lingor P.
    Mol Ther Nucl Acids 2018 June (11).


  • Imaging of neuronal tissues by x-ray diffraction and x-ray fluorescence microscopy: evaluation of contrast and biomarkers for neurodegenerative diseases.
    Carboni E, Nicolas JD, Töpperwien M, Stadelmann-Nessler C, Lingor P, Salditt T.
    Biomed Opt Express 2017  8(10), 4331-4347.PubMed

  • An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson’s Disease Patients.
    Krüger R, Lingor P, Doskas T, Henselmans JML, Danielsen EH, de Fabregues O, Stefani A, Sensken SC, Parra JC, Onuk K, Yegin A, Antonini A.
    Adv Ther. 2017 Jul;34(7):1741-1752. doi: 10.1007/s12325-017-0571-2. Epub 2017 Jun 19. PubMed

  • Deferiprone Rescues Behavioral Deficits Induced by Mild Iron Exposure in a Mouse Model of Alpha-Synuclein Aggregation.
    Carboni E, Tatenhorst L, Tönges L, Barski E, Dambeck V, Bähr M, Lingor P.
    Neuromolecular Med.  2017 Jun 16. doi: 10.1007/s12017-017-8447-9. PubMed

  • Modulation of Microglial Activity by Rho-Kinase (ROCK) Inhibition as Therapeutic Strategy in Parkinson’s Disease and Amyotrophic Lateral Sclerosis.
    Roser AE, Tönges L, Lingor P.
    Front Aging Neurosci. 2017 Apr 4;9:94. doi: 10.3389/fnagi.2017.00094. eCollection 2017. Review. PubMed

  • Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy.
    Buhmann C, Hilker R, Lingor P, Schrader C, Schwarz J, Wolz M, Reichmann H.
    J Neural Transm (Vienna, Austria : 1996). 2017 Aug;124(8):1005-1013. doi: 10.1007/s00702-017-1698-7. Epub 2017 Feb 22. PubMed

  • Rho Kinase Inhibition with Fasudil in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis-Symptomatic Treatment Potential after Disease Onset
    Günther R, Balck A, Koch JC, Nientiedt T, Sereda M, Bähr M, Lingor P, Tönges L.
    Front Pharmacol. 2017 Jan 31;8:17. doi: 10.3389/fphar.2017.00017. eCollection 2017. . PubMed

  • Alpha-synuclein and iron: two keys unlocking Parkinson’s disease.
    Lingor P, Carboni E, Koch JC.
    J Neural Transm (Vienna, Austria : 1996). 2017 Aug;124(8):973-981. doi: 10.1007/s00702-017-1695-x. Epub 2017 Feb 6. Review. PubMed


  • Calpain-mediated cleavage of collapsin response mediator protein-2 drives acute axonal degeneration.
    Zhang JN, Michel U, Lenz C, Friedel CC, Köster S, d’Hedouville Z, Tönges L, Urlaub H, Bähr M, Lingor P, Koch JC.
    Sci Rep. 2016 Nov 15;6:37050. doi: 10.1038/srep37050. PubMed

  • Calcium channel inhibition-mediated axonal stabilization improves axonal regeneration after optic nerve crush.
    Ribas VT, Lingor P.
    Neural Regen Res.2016 Aug;11(8):1245-6. doi: 10.4103/1673-5374.189184. No abstract available. PubMed

  • Loss of FBXO7 (PARK15) results in reduced proteasome activity and models a parkinsonism-like phenotype in mice.
    Vingill S, Brockelt D, Lancelin C, Tatenhorst L, Dontcheva G, Preisinger C, Schwedhelm-Domeyer N, Joseph S, Mitkovski M, Goebbels S, Nave KA, Schulz JB, Marquardt T, Lingor P, Stegmüller J.
    EMBO J. 2016 Sep 15;35(18):2008-25. doi: 10.15252/embj.201593585. Epub 2016 Aug 5. PubMed

  • [The Geriatric Patient with Parkinson’s Disease – a Neurological Challenge].
    Lingor P, Csoti I, Koschel J, Schrader C, Winkler C, Wolz M, Reichmann H.
    Fortschr Neurol Psychiatr. 2016 Jul;84 Suppl 1:S41-7. doi: 10.1055/s-0042-103585. Epub 2016 Jun 8. Review. German. PubMed

  • Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease.
    Tatenhorst L, Eckermann K, Dambeck V, Fonseca-Ornelas L, Walle H, Lopes da Fonseca T, Koch JC, Becker S, Tönges L, Bähr M, Outeiro TF, Zweckstetter M, Lingor P.
    Acta Neuropathol Commun. 2016 Apr 22;4:39. doi: 10.1186/s40478-016-0310-y. PubMed

  • Altered Expression of Growth Associated Protein-43 and Rho Kinase in Human Patients with Parkinson’s Disease.
    Saal KA, Galter D, Roeber S, Bähr M, Tönges L, Lingor P.
    Brain Pathol. 2016 Jan 8. doi: 10.1111/bpa.12346. PubMed

  • Attenuation of Axonal Degeneration by Calcium Channel Inhibitors Improves Retinal Ganglion Cell Survival and Regeneration After Optic Nerve Crush.
    Ribas VT, Koch JC, Michel U, Bähr M, Lingor P.
    Mol Neurobiol. 2016 Jan 5 PubMed


  • Elevated α-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson’s patient-derived induced pluripotent stem cells.
    Oliveira LM, Falomir-Lockhart LJ, Botelho MG, Lin KH, Wales P, Koch JC, Gerhardt E, Taschenberger H, Outeiro TF, Lingor P, Schüle B, Arndt-Jovin DJ, Jovin TM.
    Cell Death Dis. 2015 Nov 26;6:e1994. doi: 10.1038/cddis.2015.318. PubMed

  • The role of autophagy in axonal degeneration of the optic nerve.
    Koch JC, Lingor P.
    Exp Eye Res. 2015 Aug 24. pii: S0014-4835(15)30012-9. doi: 10.1016/j.exer.2015.08.016. [Epub ahead of print] Review. PubMed

  • Alpha-Synuclein Regulates Neuronal Levels of Manganese and Calcium.
    Dučić T, Carboni E, Lai B, Chen S, Michalke B, Lázaro DF, Outeiro TF, Bähr M, Barski E, Lingor P.
    ACS Chem Neurosci. 2015 Oct 21;6(10):1769-79. doi: 10.1021/acschemneuro.5b00093. Epub 2015 Aug 25. PubMed

  • Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: Consensus from an international survey and discussion program.
    Odin P, Ray Chaudhuri K, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, Krauss JK, Henriksen T, Katzenschlager R, Antonini A, Rascol O, Poewe W; National Steering Committees.
    Parkinsonism Relat Disord. 2015 Oct;21(10):1133-44. doi: 10.1016/j.parkreldis.2015.07.020. Epub 2015 Jul 23. Review. PubMed

  • Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons.
    Koch JC, Bitow F, Haack J, d’Hedouville Z, Zhang JN, Tönges L, Michel U, Oliveira LM, Jovin TM, Liman J, Tatenhorst L, Bähr M, Lingor P.
    Cell Death Dis. 2015 Jul 9;6:e1811. doi: 10.1038/cddis.2015.169. PubMed

  • Advanced stages of PD: interventional therapies and related patient-centered care.
    Krüger R, Hilker R, Winkler C, Lorrain M, Hahne M, Redecker C, Lingor P, Jost WH.
    J Neural Transm (Vienna). 2015 Jul 3. [Epub ahead of print] PubMed

  • Autophagy in degenerating axons following spinal cord injury: evidence for autophagosome biogenesis in retraction bulbs.
    Ribas VT, Lingor P.
    Neural Regen Res. 2015 Feb;10(2):198-200. doi: 10.4103/1673-5374.152367. No abstract available. PubMed

  • α-Synuclein Over-Expression Induces Increased Iron Accumulation and Redistribution in Iron-Exposed Neurons.
    Ortega R, Carmona A, Roudeau S, Perrin L, Dučić T, Carboni E, Bohic S, Cloetens P, Lingor P.
    Mol Neurobiol. 2015 Apr 2. [Epub ahead of print]. PubMed

  • AAV-mediated expression of BAG1 and ROCK2-shRNA promote neuronal survival and axonal sprouting in a rat model of rubrospinal tract injury.
    Challagundla M, Koch JC, Ribas VT, Michel U, Kügler S, Ostendorf T, Bradke F, Müller HW, Bähr M, Lingor P.
    J Neurochem.2015 Mar 11;7(3):395-404. doi: 10.1039/c4mt00339j PubMed

  • Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson’s disease.
    Carboni E, Lingor P.
    Metallomics : integrated biometal science. 2015 Mar;7(3):395-404. doi: 10.1039/c4mt00339j. Review. PubMed


  • The rho kinase inhibitor Y-27632 improves motor performance in male SOD1(G93A) mice.
    Günther R, Saal KA, Suhr M, Scheer D, Koch JC, Bähr M, Lingor P, Tönges L.
    Front Neurosci. 2014 Oct 7;8:304. doi: 10.3389/fnins.2014.00304. eCollection 2014. PubMed

  • Alpha-synuclein mutations impair axonal regeneration in models of Parkinson’s disease.
    Tönges L, Szegö EM, Hause P, Saal KA, Tatenhorst L, Koch JC, D Hedouville Z, Dambeck V, Kügler S, Dohm CP, Bähr M, Lingor P.
    Front Aging Neurosci.2014 Sep 10;6:239. doi: 10.3389/fnagi.2014.00239. eCollection 2014. PubMed

  • AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson’s disease in vitro and in vivo.
    Saal KA, Koch JC, Tatenhorst L, Szegő EM, Ribas VT, Michel U, Bähr M, Tönges L, Lingor P.
    Neurobiol Dis. 2015 Jan;73:150-62. doi: 10.1016/j.nbd.2014.09.013. Epub 2014 Oct 2. PubMed

  • Viral vector-mediated downregulation of RhoA increases survival and axonal regeneration of retinal ganglion cells.
    Koch JC, Tönges L, Michel U, Bähr M, Lingor P.
    Front Cell Neurosci. 2014 Sep 5;8:273. doi: 10.3389/fncel.2014.00273. eCollection 2014. PubMed

  • BAG1 is Neuroprotective in In Vivo and In Vitro Models of Parkinson’s Disease.
    Kermer P, Köhn A, Schnieder M, Lingor P, Bähr M, Liman J, Dohm CP.
    J Mol Neurosci. 2015 Mar;55(3):587-95. doi: 10.1007/s12031-014-0396-2. Epub 2014 Aug. PubMed

  • Early and sustained activation of autophagy in degenerating axons after spinal cord injury.
    Ribas VT, Schnepf B, Challagundla M, Koch JC, Bähr M, Lingor P.
    Brain pathol. 2015 Mar;25(2):157-70. doi: 10.1111/bpa.12170. Epub 2014 Sep 12. PubMed

  • Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson disease.
    Tatenhorst L, Tönges L, Saal KA, Koch JC, Szegő EM, Bähr M, Lingor P.
    J Neuropathol Exp Neurol. 2014 Aug;73(8):770-9. doi: 10.1097/NEN.0000000000000095. PubMed

  • ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS.
    Koch JC, Tönges L, Barski E, Michel U, Bähr M, Lingor P.
    Cell Death Dis. 2014 May 15;5:e1225. doi: 10.1038/cddis.2014.191. PubMed

  • Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis.
    Tönges L, Günther R, Suhr M, Jansen J, Balck A, Saal KA, Barski E, Nientied T, Götz AA, Koch JC, Mueller BK, Weishaupt JH, Sereda MW, Hanisch UK, Bähr M, Lingor P.
    Glia. 2014 Feb;62(2):217-32. doi: 10.1002/glia.22601. Epub 2013 Dec 6. PubMed


  • Acute onset of adult Alexander disease.
    Schmidt H, Kretzschmar B, Lingor P, Pauli S, Schramm P, Otto M, Ohlenbusch A, Brockmann K.
    J Neurol Sci. 2013 Aug 15;331(1-2):152-4. doi: 10.1016/j.jns.2013.05.006. Epub 2013 May 23. PubMed

  • Unilateral phrenic nerve lesion in Lyme neuroborreliosis.
    Djukic M, Larsen J, Lingor P, Nau R.
    BMC Pulm Med. 2013 Jan 18;13:4. doi: 10.1186/1471-2466-13-4. PubMed

  • Upregulation of reggie-1/flotillin-2 promotes axon regeneration in the rat optic nerve in vivo and neurite growth in vitro.
    Koch JC, Solis GP, Bodrikov V, Michel U, Haralampieva D, Shypitsyna A, Tönges L, Bähr M, Lingor P, Stuermer CA.
    Neurobiol Dis. 2013 Mar;51:168-76. doi: 10.1016/j.nbd.2012.11.007. Epub 2012 Nov 19. PubMed

  • X-ray Fluorescence Analysis of Iron and Manganese Distribution in Primary Dopaminergic Neurons.
    Dučić T, Barski E, Salome M, Koch JC, Bähr M, Lingor P.
    J Neurochem. 2012 Oct 27. PubMed


  • Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson’s disease.
    Tönges L, Frank T, Tatenhorst L, Saal KA, Koch JC, Szego EM, Bähr M, Weishaupt JH, Lingor P.
    Brain. 2012 Oct 19. PubMed

  • Guidelines for the use and interpretation of assays for monitoring autophagy.
    Klionsky DJ, et al.
    Autophagy. 2012 Apr;8(4):445-544. PubMed

  • Clinical testing and spinal cord removal in a mouse model for amyotrophic lateral sclerosis (ALS).
    Günther R, Suhr M, Koch JC, Bähr M, Lingor P, Tönges L.
    J Vis Exp. 2012 Mar 17;(61). pii: 3936. doi: 10.3791/3936. PubMed

  • Axonal degeneration as a therapeutic target in the CNS.
    Lingor P, Koch JC, Tönges L, Bähr M.
    Cell Tissue Res. 2012 Jul;349(1):289-311. doi: 10.1007/s00441-012-1362-3. Epub 2012 Mar 6. Review. PubMed


  • ROCKing Regeneration: Rho Kinase Inhibition as Molecular Target for Neurorestoration.
    Tönges L, Koch JC, Bähr M, Lingor P.
    Front Mol Neurosci. 2011 Nov 3;4:39. doi: 10.3389/fnmol.2011.00039. eCollection 2011. PubMed

  • Imaging of rat optic nerve axons in vivo.
    Koch JC, Knöferle J, Tönges L, Michel U, Bähr M, Lingor P.
    Nat Protoc. 2011 Nov 3;6(12):1887-96. doi: 10.1038/nprot.2011.403. PubMed

  • The Spinal Muscular Atrophy disease protein SMN is linked to the Rho-kinase pathway via profilin
    Nölle A, Zeug A, Bergeijk J, Tönges L, Gerhard R, Brinkmann H, Al Rayes S, Apkhazava D, Jablonka S, O´mer J, Srivastav R, Baasner A, Lingor P, Wirth B, Ponimaskin E, Niedenthal R, Grothe C, Claus P.
    Hum Mol Gen. 2011 Dec 15;20(24):4865-78. Epub 2011 Sep 14. PubMed

  • Current prospects in optic nerve protection and regeneration: sixth ARVO/Pfizer Ophthalmics Research Institute conference.
    Limb GA, Martin KR; Sixth ARVO/Pfizer Ophthalmics Research Institute Conference Working Group.
    Invest Ophthalmol Vis Sci. 2011 Jul 29;52(8):5941-54. doi: 10.1167/iovs.10-6894. No abstract available. PubMed

  • Plasmids containing NRSE/RE1-sites enhance neurite outgrowth of retinal ganglion cells via cytoplasmic sequestration of REST independent of NRSE dsRNA expression.
    Koch JC, Barski L, Lingor P, Bähr M, Michel U (2011).
    FEBS J.2011 Sep;278(18):3472-83. doi: 10.1111/j.1742-4658.2011.08269.x. PubMed
  • JNK isoforms differentially regulate neurite growth and regeneration in dopaminergic neurons in vitro.
    Tönges L, Planchamp V, Koch JC, Herdegen T, Bähr M, Lingor P (2011) .
    J Mol Neurosci. 2011 Oct;45(2):284-93. Epub 2011 Apr 6. PubMed

  • Hepatocyte growth factor protects retinal ganglion cells by increasing neuronal survival and axonal regeneration in vitro and in vivo.
    Tönges L, Ostendorf T, Lamballe F, Genestine M, Dono R, Koch JC, Bähr M, Maina F, Lingor P.
    J Neurochem. 2011 Jun;117(5):892-903. doi: 10.1111/j.1471-4159.2011.07257.x. PubMed

  • [Arndt-Gottron syndrome with encephalopathy: complete recovery after immunosuppressive therapy].
    Schmidt H, Schramm P, Fuchs T, Bähr M, Lingor P.
    Nervenarzt. 2011 Oct;82(10):1325-9. doi: 10.1007/s00115-011-3266-y. German. No abstract available. PubMed


  • Cerebellar-type multiple system atrophy presenting with leucoencephalopathy.
    Göricke B, Lingor P, Stadelmann-Nessler C, Bähr M, Kastrup A, Kermer P.
    J Neurol Neurosurg Psychiatry. 2012 Feb;83(2):230-2. doi: 10.1136/jnnp.2010.220822. Epub 2010 Nov 28. No abstract available. PubMed

  • Acute axonal degeneration in vivo is attenuated by inhibition of autophagy in a calcium-dependent manner.
    Koch JC, Knöferle J, Tönges L, Ostendorf T, Bähr M, Lingor P.
    Autophagy. 2010 Jul;6(5):658-9. doi: 10.4161/auto.6.5.12188. Epub 2010 Jul 1. PubMed

  • Mechanisms of acute axonal degeneration in the optic nerve in vivo.
    Knöferle J, Koch JC, Ostendorf T, Michel U, Planchamp V, Vutova P, Tönges L, Stadelmann C, Brück W, Bähr M, Lingor P.
    Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):6064-9. doi: 10.1073/pnas.0909794107. Epub 2010 Mar 15. PubMed

  • TGF-beta 1 enhances neurite outgrowth via regulation of proteasome function and EFABP.
    Knöferle J, Ramljak S, Koch JC, Tönges L, Asif AR, Michel U, Wouters FS, Heermann S, Krieglstein K, Zerr I, Bähr M, Lingor P.
    Neurobiol Dis. 2010 Jun;38(3):395-404. doi: 10.1016/j.nbd.2010.02.011. Epub 2010 Mar 6. PubMed


  • Combined inhibition of Cdk5 and ROCK additively increase cell survival, but not the regenerative response in regenerating retinal ganglion cells.
    Bermel C, Tönges L, Planchamp V, Gillardon F, Weishaupt JH, Dietz GP, Bähr M, Lingor P.
    Mol Cell Neurosci. 2009 Dec;42(4):427-37. doi: 10.1016/j.mcn.2009.09.005. Epub 2009 Sep 25. PubMed

  • Role of n-type voltage-dependent calcium channels in autoimmune optic neuritis.
    Gadjanski I, Boretius S, Williams SK, Lingor P, Knöferle J, Sättler MB, Fairless R, Hochmeister S, Sühs KW, Michaelis T, Frahm J, Storch MK, Bähr M, Diem R.
    Ann Neurol. 2009 Jul;66(1):81-93. doi: 10.1002/ana.21668. PubMed


  • BAG1 promotes axonal outgrowth and regeneration in vivo via Raf-1 and reduction of ROCK activity.
    Planchamp V, Bermel C, Tönges L, Ostendorf T, Kügler S, Reed JC, Kermer P, Bähr M, Lingor P.
    Brain: a journal of neurology. 2008 Oct;131(Pt 10):2606-19. doi: 10.1093/brain/awn196. Epub 2008 Aug 29. PubMed

  • Angiographic CT with intravenous administration of contrast medium is a noninvasive option for follow-up after intracranial stenting.
    Buhk JH, Lingor P, Knauth M.
    Neuroradiology. 2008 Apr;50(4):349-54. doi: 10.1007/s00234-007-0342-x. Epub 2008 Feb 2. PubMed

  • ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal ganglion cells.
    Lingor P, Tönges L, Pieper N, Bermel C, Barski E, Planchamp V, Bähr M.
    Brain : a journal of neurology. 2008 Jan;131(Pt 1):250-63. Epub 2007 Dec 5. PubMed

  • Identification of new kinase clusters required for neurite outgrowth and retraction by a loss-of-function RNA interference screen.
    Loh SH, Francescut L, Lingor P, Bähr M, Nicotera P.
    Cell Death Differ. 2008 Feb;15(2):283-98. Epub 2007 Nov 16. PubMed

  • Membrane-permeable Bcl-xL prevents MPTP-induced dopaminergic neuronal loss in the substantia nigra.
    Dietz GP, Stockhausen KV, Dietz B, Falkenburger BH, Valbuena P, Opazo F, Lingor P, Meuer K, Weishaupt JH, Schulz JB, Bähr M.
    J Neurochem. 2008 Feb;104(3):757-65. Epub 2007 Nov 6. PubMed


  • Targeting neurological disease with RNAi.
    Lingor P, Bähr M.
    Mol BioSyst. 2007 Nov;3(11):773-80. Epub 2007 Aug 29. Review. PubMed

  • Galectin-1 expression in human glioma cells: modulation by ionizing radiation and effects on tumor cell proliferation and migration.
    Strik HM, Schmidt K, Lingor P, Tönges L, Kugler W, Nitsche M, Rabinovich GA, Bähr M.
    Oncol Rep. 2007 Aug;18(2):483-8. PubMed

  • Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo.
    Lingor P, Teusch N, Schwarz K, Mueller R, Mack H, Bähr M, Mueller BK.
    J Neurochem. 2007 Oct;103(1):181-9. Epub 2007 Jul 2. PubMed

  • Cyclin-dependent kinase 5 is an upstream regulator of mitochondrial fission during neuronal apoptosis.
    Meuer K, Suppanz IE, Lingor P, Planchamp V, Göricke B, Fichtner L, Braus GH, Dietz GP, Jakobs S, Bähr M, Weishaupt JH.
    Cell Death Differ. 2007 Apr;14(4):651-61. Epub 2007 Jan 12. PubMed


  • Brain repair: Experimental treatment strategies, neuroprotective and repair strategies in the lesioned adult CNS.
    Bähr M, Lingor P.
    Adv Exp Med Biol. 2006;557:148-63. Review. No abstract available. PubMed

  • The long processes of short interfering RNAs–RNA interference and its implications in neuronal cells.
    Lingor P, Michel U, Bähr M.
    Neurodegener Dis. 2004;1(1):3-8. Review. PubMed

  • Imino-tetrahydro-benzothiazole derivatives as p53 inhibitors: discovery of a highly potent in vivo inhibitor and its action mechanism.
    Pietrancosta N, Moumen A, Dono R, Lingor P, Planchamp V, Lamballe F, Bähr M, Kraus JL, Maina F.
    J Med Chem. 2006 Jun 15;49(12):3645-52. PubMed

  • Stearylated octaarginine and artificial virus-like particles for transfection of siRNA into primary rat neurons.
    Tönges L, Lingor P, Egle R, Dietz GP, Fahr A, Bähr M.
    RNA.  2006 Jul;12(7):1431-8. Epub 2006 May 12. PubMed

  • Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson’s disease.
    Meuer K, Pitzer C, Teismann P, Krüger C, Göricke B, Laage R, Lingor P, Peters K, Schlachetzki JC, Kobayashi K, Dietz GP, Weber D, Ferger B, Schäbitz WR, Bach A, Schulz JB, Bähr M, Schneider A, Weishaupt JH.
    J Neurochem. 2006 May;97(3):675-86. Epub 2006 Mar 29. PubMed


  • Down-regulation of apoptosis mediators by RNAi inhibits axotomy-induced retinal ganglion cell death in vivo.
    Lingor P, Koeberle P, Kügler S, Bähr M.
    Brain : a journal of neurology”>Brain. 2005 Mar;128(Pt 3):550-8. Epub 2005 Jan 19. PubMed

  • Functional applications of novel Semliki Forest virus vectors are limited by vector toxicity in cultures of primary neurons in vitro and in the substantia nigra in vivo.
    Lingor P, Schöll U, Bähr M, Kügler S.
    Exp Brain Res. 2005 Mar;161(3):335-42. Epub 2004 Oct 20. PubMed


  • Rifampicin inhibits neurodegeneration in the optic nerve transection model in vivo and after 1-methyl-4-phenylpyridinium intoxication in vitro.
    Kilic U, Kilic E, Lingor P, Yulug B, Bähr M.
    Acta neuropathol. 2004 Jul;108(1):65-8. Epub 2004 May 8. PubMed

  • Transfection of “naked” siRNA results in endosomal uptake and metabolic impairment in cultured neurons.
    Lingor P, Michel U, Schöll U, Bähr M, Kügler S.
    Biochem Biophys Res Commun. 2004 Mar 19;315(4):1126-33. PubMed


  • Paraneoplastic polymyositis in recurring adrenal gland carcinoma.
    Lingor P, von Boetticher D, Bähr M, Fassbender K.
    Lancet. Neurol. 2003 Jul;2(7):435-6. No abstract available. PubMed

  • Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units.
    Kügler S, Lingor P, Schöll U, Zolotukhin S, Bähr M.
    Virology. 2003 Jun 20;311(1):89-95. PubMed


  • GDF-15/MIC-1 a novel member of the TGF-beta superfamily.
    Strelau J, Böttner M, Lingor P, Suter-Crazzolara C, Galter D, Jaszai J, Sullivan A, Schober A, Krieglstein K, Unsicker K.
    J Neural Transm Suppl. 2000;(60):273-6. Review. PubMed

  • GDNF and NT-4 protect midbrain dopaminergic neurons from toxic damage by iron and nitric oxide.
    Lingor P, Unsicker K, Krieglstein K.
    Exp Neurol. 2000 May;163(1):55-62. PubMed

  • Growth/differentiation factor-15/macrophage inhibitory cytokine-1 is a novel trophic factor for midbrain dopaminergic neurons in vivo.
    Strelau J, Sullivan A, Böttner M, Lingor P, Falkenstein E, Suter-Crazzolara C, Galter D, Jaszai J, Krieglstein K, Unsicker K.
    J Neurosci. 2000 Dec 1;20(23):8597-603. PubMed


  • Midbrain dopaminergic neurons are protected from radical induced damage by GDF-5 application. Short communication.
    Lingor P, Unsicker K, Krieglstein K.
    J Neural transm (Vienna). 1999;106(2):139-44. PubMed